Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Deferred Revenue (2021 - 2026)

Ocular Therapeutix has reported Current Deferred Revenue over the past 9 years, most recently at $14.0 million for Q1 2026.

  • For Q1 2026, Current Deferred Revenue rose 21775.0% year-over-year to $14.0 million; the TTM value through Mar 2026 reached $14.0 million, up 21775.0%, while the annual FY2025 figure was $14.0 million, 10837.5% up from the prior year.
  • Current Deferred Revenue for Q1 2026 was $14.0 million at Ocular Therapeutix, roughly flat from $14.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $14.6 million in Q2 2023 and troughed at $64000.0 in Q1 2025.
  • A 5-year average of $8.5 million and a median of $14.0 million in 2025 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 99.11% in 2024 and later skyrocketed 21775.0% in 2026.
  • Year by year, Current Deferred Revenue stood at $14.0 million in 2022, then grew by 3.06% to $14.4 million in 2023, then plummeted by 99.11% to $128000.0 in 2024, then skyrocketed by 10837.5% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
  • Business Quant data shows Current Deferred Revenue for OCUL at $14.0 million in Q1 2026, $14.0 million in Q4 2025, and $14.0 million in Q3 2025.